HK1211572A1 - Piperidinium quaternary salts - Google Patents
Piperidinium quaternary salts Download PDFInfo
- Publication number
- HK1211572A1 HK1211572A1 HK15112219.3A HK15112219A HK1211572A1 HK 1211572 A1 HK1211572 A1 HK 1211572A1 HK 15112219 A HK15112219 A HK 15112219A HK 1211572 A1 HK1211572 A1 HK 1211572A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- piperidinium
- quaternary salts
- acetoxy
- propoxy
- diphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681415P | 2012-08-09 | 2012-08-09 | |
| US61/681,415 | 2012-08-09 | ||
| PCT/US2013/052626 WO2014025569A1 (en) | 2012-08-09 | 2013-07-30 | Piperidinium quaternary salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1211572A1 true HK1211572A1 (en) | 2016-05-27 |
Family
ID=50068488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15112219.3A HK1211572A1 (en) | 2012-08-09 | 2013-07-30 | Piperidinium quaternary salts |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9896416B2 (https=) |
| EP (1) | EP2882711B1 (https=) |
| JP (1) | JP6345665B2 (https=) |
| KR (2) | KR102240999B1 (https=) |
| CN (2) | CN108658842A (https=) |
| AU (1) | AU2013300009B2 (https=) |
| BR (1) | BR112015002832B1 (https=) |
| CA (1) | CA2881182C (https=) |
| EA (1) | EA029678B9 (https=) |
| HK (1) | HK1211572A1 (https=) |
| IL (1) | IL236996A0 (https=) |
| IN (1) | IN2015DN01018A (https=) |
| MX (1) | MX356386B (https=) |
| WO (1) | WO2014025569A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978201A1 (en) | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Use of oxybutynin transdermal formulations to reduce side effects associated with muscarinic agonists |
| US20180360845A1 (en) * | 2015-07-20 | 2018-12-20 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| CN114868435B (zh) | 2019-08-22 | 2023-12-26 | 欧芬诺有限责任公司 | 针对多址接入的策略控制 |
| CN117018194B (zh) * | 2023-07-26 | 2026-04-17 | 同济大学 | 毒蕈碱型受体5型受体拮抗剂的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD106643A1 (https=) * | 1973-07-12 | 1974-06-20 | ||
| CN1285348A (zh) | 1999-08-20 | 2001-02-28 | 广东康美药业股份有限公司 | 盐酸丙哌维林合成工艺 |
| DE10129832A1 (de) * | 2001-06-17 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
| CA2384922C (en) * | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
| KR100510788B1 (ko) | 2003-07-22 | 2005-08-26 | 동방에프티엘 주식회사 | 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법 |
| KR100500760B1 (ko) | 2003-07-22 | 2005-07-14 | 동방에프티엘 주식회사 | 염산 프로피베린의 제조방법 |
| EP1713473B1 (en) * | 2004-02-06 | 2013-03-13 | MEDA Pharma GmbH & Co. KG | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
| CA2618933C (en) * | 2005-08-12 | 2016-09-20 | Dietmar Plenz | Neuronal avalanche assay |
| CN1951938A (zh) * | 2005-10-21 | 2007-04-25 | 刘丽娅 | 戊乙奎醚季铵盐及其衍生物 |
| SE0600876L (sv) | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
| CN101490003A (zh) | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
| WO2007123465A1 (en) * | 2006-04-24 | 2007-11-01 | Astrazeneca Ab | New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder |
| EP2470504B1 (en) * | 2010-03-15 | 2013-10-16 | Ramesha Andagar Ramakrishna | Synthesis of propiverine hydrochloride |
| KR101149821B1 (ko) | 2010-04-05 | 2012-05-24 | 하나제약 주식회사 | 디페닐아세테이트 유도체의 새로운 제조방법 |
| CN102218063B (zh) | 2011-04-12 | 2013-03-13 | 贵州神奇制药有限公司 | 盐酸丙哌维林药物的制备方法和产品及其检测方法 |
| EP4035668A1 (en) * | 2012-09-05 | 2022-08-03 | Chase Pharmaceuticals Corporation | Anticholinergic neuroprotective composition and methods |
-
2013
- 2013-07-30 MX MX2015001769A patent/MX356386B/es active IP Right Grant
- 2013-07-30 CA CA2881182A patent/CA2881182C/en active Active
- 2013-07-30 KR KR1020207005139A patent/KR102240999B1/ko not_active Expired - Fee Related
- 2013-07-30 AU AU2013300009A patent/AU2013300009B2/en not_active Ceased
- 2013-07-30 KR KR20157006047A patent/KR20150040355A/ko not_active Ceased
- 2013-07-30 CN CN201810664740.3A patent/CN108658842A/zh active Pending
- 2013-07-30 BR BR112015002832-2A patent/BR112015002832B1/pt not_active IP Right Cessation
- 2013-07-30 EP EP13827594.6A patent/EP2882711B1/en active Active
- 2013-07-30 IN IN1018DEN2015 patent/IN2015DN01018A/en unknown
- 2013-07-30 CN CN201380042085.3A patent/CN104603108A/zh active Pending
- 2013-07-30 JP JP2015526567A patent/JP6345665B2/ja not_active Expired - Fee Related
- 2013-07-30 HK HK15112219.3A patent/HK1211572A1/xx unknown
- 2013-07-30 US US14/419,381 patent/US9896416B2/en not_active Expired - Fee Related
- 2013-07-30 WO PCT/US2013/052626 patent/WO2014025569A1/en not_active Ceased
- 2013-07-30 EA EA201500209A patent/EA029678B9/ru unknown
-
2015
- 2015-01-29 IL IL236996A patent/IL236996A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA029678B1 (ru) | 2018-04-30 |
| MX2015001769A (es) | 2015-05-08 |
| KR20150040355A (ko) | 2015-04-14 |
| EP2882711A4 (en) | 2016-02-10 |
| EP2882711B1 (en) | 2017-10-25 |
| KR102240999B1 (ko) | 2021-04-15 |
| JP6345665B2 (ja) | 2018-06-20 |
| US20150203452A1 (en) | 2015-07-23 |
| CN108658842A (zh) | 2018-10-16 |
| EA201500209A1 (ru) | 2015-05-29 |
| EA029678B9 (ru) | 2018-07-31 |
| AU2013300009B2 (en) | 2017-06-15 |
| CA2881182C (en) | 2021-01-26 |
| US9896416B2 (en) | 2018-02-20 |
| WO2014025569A1 (en) | 2014-02-13 |
| EP2882711A1 (en) | 2015-06-17 |
| CA2881182A1 (en) | 2014-02-13 |
| BR112015002832A2 (https=) | 2017-07-04 |
| IL236996A0 (en) | 2015-03-31 |
| MX356386B (es) | 2018-05-28 |
| AU2013300009A1 (en) | 2015-02-26 |
| KR20200022522A (ko) | 2020-03-03 |
| BR112015002832B1 (pt) | 2022-08-16 |
| IN2015DN01018A (https=) | 2015-06-26 |
| JP2015524469A (ja) | 2015-08-24 |
| CN104603108A (zh) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201405101B (en) | "new indolizine compounds, a process for their preparation and pharmaceutical compositions containing them." | |
| WO2016064082A3 (ko) | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 | |
| EA201290984A1 (ru) | Гелеобразные фармацевтические композиции, препятствующие злоупотреблению | |
| EP4249055A3 (en) | Tofacitinib oral sustained release dosage forms | |
| LT2808325T (lt) | Pakeistieji azolai, antivirusinis aktyvus ingredientas, farmacinė kompozicija, jų gavimo ir panaudojimo būdas | |
| HK1213779A1 (zh) | 用於立即和延长释放的组合物 | |
| WO2011120904A3 (en) | A fast dissolving pharmaceutical composition | |
| IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
| IL222578A0 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| HK1215166A1 (zh) | 具有β2肾上腺素激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 | |
| EP2900272A4 (en) | MISSIBLE PHARMACEUTICAL COMPOSITION WITH KONJAC-GLUCOMANNAN | |
| WO2011108826A3 (en) | Complex formulation for oral administration comprising probiotic formulation and 5-ht4 receptor agonist and method for the preparation thereof | |
| WO2014076712A3 (en) | Lurasidone hydrochloride solid dispersion | |
| WO2011120903A3 (en) | A fast dissolving pharmaceutical composition | |
| WO2014179567A3 (en) | Methods and compositions for treating beta-thalassemia and sickle cell disease | |
| CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| GEP201706739B (en) | Compositions comprising vortioxetine and donepezil | |
| MX2016008369A (es) | Composicion farmaceutica que incluye palonosetron. | |
| HK1211572A1 (en) | Piperidinium quaternary salts | |
| WO2014133744A3 (en) | Oral care compositions | |
| HK1224219A1 (zh) | 多颗粒药物输送系统 | |
| IL246298A0 (en) | History of piperidine, their preparation and pharmaceutical preparations containing them | |
| WO2013169746A3 (en) | N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide | |
| IL233055A0 (en) | (1r,r4) 7-oxo-2-azabicyclo [2.2.2] oct-5-ene and its derivatives | |
| WO2011014003A3 (en) | (+)-3-hydroxymorphinan derivatives as neuroprotectants |